Mirjana Jovanović

Dr. Mirjana Jovanović


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMarija Kosić
Marija Kosić
VPVladislav Pajović
Vladislav Pajović
MJMirjana Jovanović
Mirjana Jovanović
NJNina Japundzic-Zigon
Nina Japundzic-Zigon
Doxorubicin (DOX) is an effective drug for the treatment of solid tumors and hematological malignancies in both children and adults. The most serious side effect is doxorubicin-induced cardiotoxicity (DIC), which can lead to cardiomyopathy and irreversible and highly fatal cardiac decompensation. The precise mechanisms underlying DIC are not fully understood, and currently, no fully effective preventive or therapeutic strategies exist. Drug repositioning has emerged as a promising approach to mitigate DIC, leveraging existing safety profiles while potentially reducing the time and cost of clinical translation. In this review, we summarize current evidence on drug repurposing for DIC, with a particular focus on the antidepressant paroxetine, which shows potential cardioprotective effects beyond its established role as a selective serotonin reuptake inhibitor (SSRI).

4 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VPVladislav Pajovic
Vladislav Pajovic
MKMarija Kosić
Marija Kosić
MJMirjana Jovanović
Mirjana Jovanović
NJNina Japundzic-Zigon
Nina Japundzic-Zigon
Cardiomyopathies represent a heterogeneous group of diseases that lead to functional and structural impairment of the myocardium, frequently culminating in heart failure. Due to ethical and technical constraints inherent to human studies, rat models have become indispensable in experimental cardiology. Transthoracic echocardiography represents one of the most commonly used methods for assessing cardiac structure and function in experimental rat models of cardiomyopathy, due to its accessibility, non-invasiveness, ease of use, safety and cost-effectiveness. Almost all echocardiographic examinations in rats require a certain level of pharmacological sedation or general anesthesia to immobilize the animal and reduce motion-induced artifacts. A review of the literature reveals that only a few anesthetics are used in experimental practice. By far the two most prevalent choices are isoflurane and the ketamine-xylazine combination. Less frequently used are pentobarbital, the tiletamine-zolazepam combination, sevoflurane, and acepromazine. However, the interpretation of echocardiographic findings in experimental animals can be significantly biased by the effects of anesthesia primarily on the autonomic nervous system and cardiac contractility. Therefore the choice of anesthetic or sedative protocol represents an important, yet insufficiently standardized, methodological variable in the echocardiographic assessment of rat models of cardiomyopathy. Here we discuss the bias introduced by the use of sedatives/anesthetics when performing echocardiography in different rat models of experimental cardiomyopathy.

1 January 2025
Verified
Conference Paper
Closed access
JOJelena Nesovic Ostojic
Jelena Nesovic Ostojic
Sanjin KovacevicSanjin Kovacevic
Sanjin Kovacevic
NMNikola Mitovic
Nikola Mitovic
Aleksandra NenadovicAleksandra Nenadovic
Aleksandra Nenadovic
AVAndrija Vuković
Andrija Vuković
MJMirjana Jovanović
Mirjana Jovanović
Renal function is an important aspect to evaluate in cardiovascular patients because kidney function and heart function are closely interconnected. Cardiorenal syndrome refers to this complex relationship, where either heart or kidney dysfunction can lead to worsening of the other, making their management more complex and challenging. Renal function in cardiovascular patietns should be assessed at the time of diagnosis of cardiovascular conditions (e.g., heart failure, coronary artery disease, or hypertension), as kidney function can impact the treatment plan and prognosis; during hospitalization, when patietns are admitted for conditions like heart failure, renal function should be evaluated to monitor for acute kidney injury (AKI) or worsening chronic kidney disease (CKD). After surgeries such as coronary artery bypass grafting or valve replacement, renal function should be closely monitored due to the risk of postoperative renal complications. If a patient with known cardiovascular disease develops new or worsening symptoms (e.g., edema, dyspnea, or fatigue), renal function should be evaluated as it may indicate worsening heart failure or fluid overload. Certain cardiovascular drugs (like ACE inhibitors, ARBs, diuretics, and anticoagulants) are cleared by the kidneys, and renal function should be assessed to adjust doses and minimize the risk of toxicity. For patients with a known history of CKD, regular renal function evaluation is important for monitoring disease progression and managing cardiovascular risk. It is also essential to regularly evaluate renal function in patients with hypertension, diabetes, or metabolic syndrome that are risk factors for both cardiovascular and kidney diseases. Evaluating renal function in cardiovascular patients is essential to: detect and manage cardiorenal syndrome early; adjust cardiovascular medication dosages and avoid toxicities; guide fluid and electrolyte management; reduce cardiovascular and renal complications, and imrove prognosis and quality of life. By closely monitoring renal function, clinicians can optimize both cardiovascular and renal outcomes, helping to prevent complications and improve the overall health of these patients. Serum creatinine is a standard measure of kidney function. From serum creatinine, the eGFR is calculated to assess kidney function. A decline in eGFR (usually <60 mL/min/1.73m²) indicates reduced kidney function. eGFR may be overestimated in patients with high muscle mass or malnutrition, and underestimating kidney function in patients with obesity or edema. Particularly in hospitalized or critically ill patients, urine output is an important marker of renal function. Decreased urine output (oliguria) may indicate acute kidney injury or worsening heart failure. Proteinuria and hematuria can indicate kidney damage. In patients with heart failure, proteinuria may be a sign of kidney involvement and should be assessed regularly. BUN is another marker of kidney function but is less specific than creatinine and can be influenced by factors such as dehydration, diet, and liver function. Electrolytes (e.g., potassium, sodium, and bicarbonate) should be monitored, as disturbances in electrolyte balance (e.g., hyperkalemia, hyponatremia) are common in patients with kidney dysfunction and heart failure. Neurohormonal biomarkers like BNP (B-type natriuretic peptide) or proBNP can be elevated in both heart failure and renal dysfunction. Evaluating these levels can help assess the severity of heart failure and guide management. A rise in creatinine levels or a decrease in urine output can indicate AKI. Monitoring trends in these values can help in early identification and intervention. Risk scoring: Use of scoring systems like the RIFLE (Risk, Injury, Failure, Loss, End-stage renal disease) or AKIN (Acute Kidney Injury Network) criteria may help in determining the severity of AKI.

1 January 2026 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
NMNemanja Marković
Nemanja Marković
SMSvetozar Mijušković
Svetozar Mijušković
MJMirjana Jovanović
Mirjana Jovanović
NMNikola Mitovic
Nikola Mitovic
Aleksandra NenadovicAleksandra Nenadovic
Aleksandra Nenadovic
JOJelena Nesovic Ostojic
Jelena Nesovic Ostojic
Introduction: Bones are fundamental components of the skeletal system that undergo continuous remodeling throughout life. Osteoclasts are responsible for bone resorption, while osteoblasts form new bone matrix and indirectly influence osteoclast differentiation through signaling pathways involving molecules such as M-CSF, c-Fms, GRB2, ERK, PI3K, and Akt. To maintain bone health, increasing attention is being given to nutritional interventions, including the Mediterranean diet, which is rich in bioactive compounds. The aim of this study was to perform an in silico analysis of potential interactions between the most prevalent bioactive compounds of the Mediterranean diet and the key proteins of the osteoclast differentiation signaling pathway. Materials and Methods: A library comprising 115 predominant bioactive compounds from the Mediterranean diet was constructed based on literature data. Protein structures obtained via crystallography were used as targets in molecular docking simulations to predict interactions between ligands and receptors. Results: Most ligands did not show significant interactions with the investigated proteins (ΔG > -7 kcal/mol), except in the case of Akt protein. For this protein, a larger number of ligands demonstrated ΔG values < -7 kcal/mol. The five most potent ligands (salvianolic acid, apigenin, diosmin, mangiferin and sylbin) bound to amino acid sequences forming the active site of the receptor, indicating a potential inhibitory effect. Conclusion: The in silico analysis suggests that bioactive components of the Mediterranean diet possess potential to inhibit Akt protein (protein kinase B), thereby opening new perspectives for their application in modulating osteoclast activity and developing novel strategies for maintaining bone health.